239 related articles for article (PubMed ID: 15140578)
1. Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H.
Sánchez-Corral P; González-Rubio C; Rodríguez de Córdoba S; López-Trascasa M
Mol Immunol; 2004 May; 41(1):81-4. PubMed ID: 15140578
[TBL] [Abstract][Full Text] [Related]
2. The role of defective complement control in hemolytic uremic syndrome.
Zipfel PF; Misselwitz J; Licht C; Skerka C
Semin Thromb Hemost; 2006 Mar; 32(2):146-54. PubMed ID: 16575689
[TBL] [Abstract][Full Text] [Related]
3. Functional evaluation of factor H genetic and acquired abnormalities: application for atypical hemolytic uremic syndrome (aHUS).
Roumenina LT; Roquigny R; Blanc C; Poulain N; Ngo S; Dragon-Durey MA; Frémeaux-Bacchi V
Methods Mol Biol; 2014; 1100():237-47. PubMed ID: 24218264
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome.
Vaziri-Sani F; Holmberg L; Sjöholm AG; Kristoffersson AC; Manea M; Frémeaux-Bacchi V; Fehrman-Ekholm I; Raafat R; Karpman D
Kidney Int; 2006 Mar; 69(6):981-8. PubMed ID: 16528247
[TBL] [Abstract][Full Text] [Related]
5. Atypical hemolytic uremic syndrome.
Kavanagh D; Goodship TH; Richards A
Semin Nephrol; 2013 Nov; 33(6):508-30. PubMed ID: 24161037
[TBL] [Abstract][Full Text] [Related]
6. Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon?
Kavanagh D; Pappworth IY; Anderson H; Hayes CM; Moore I; Hunze EM; Bennaceur K; Roversi P; Lea S; Strain L; Ward R; Plant N; Nailescu C; Goodship TH; Marchbank KJ
Clin J Am Soc Nephrol; 2012 Mar; 7(3):417-26. PubMed ID: 22223611
[TBL] [Abstract][Full Text] [Related]
7. Hemolytic uremic syndrome: a factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells.
Heinen S; Józsi M; Hartmann A; Noris M; Remuzzi G; Skerka C; Zipfel PF
J Am Soc Nephrol; 2007 Feb; 18(2):506-14. PubMed ID: 17229916
[TBL] [Abstract][Full Text] [Related]
8. The endothelial glycocalyx as a potential modifier of the hemolytic uremic syndrome.
Boels MG; Lee DH; van den Berg BM; Dane MJ; van der Vlag J; Rabelink TJ
Eur J Intern Med; 2013 Sep; 24(6):503-9. PubMed ID: 23357408
[TBL] [Abstract][Full Text] [Related]
9. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome.
Józsi M; Strobel S; Dahse HM; Liu WS; Hoyer PF; Oppermann M; Skerka C; Zipfel PF
Blood; 2007 Sep; 110(5):1516-8. PubMed ID: 17495132
[TBL] [Abstract][Full Text] [Related]
10. Cutting edge: localization of the host recognition functions of complement factor H at the carboxyl-terminal: implications for hemolytic uremic syndrome.
Pangburn MK
J Immunol; 2002 Nov; 169(9):4702-6. PubMed ID: 12391176
[TBL] [Abstract][Full Text] [Related]
11. A user's guide to the interactive Web database of factor H-associated hemolytic uremic syndrome.
Saunders RE; Perkins SJ
Semin Thromb Hemost; 2006 Mar; 32(2):160-8. PubMed ID: 16575691
[TBL] [Abstract][Full Text] [Related]
12. Complement activation in diseases presenting with thrombotic microangiopathy.
Meri S
Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
[TBL] [Abstract][Full Text] [Related]
13. Factor H-related protein 1 neutralizes anti-factor H autoantibodies in autoimmune hemolytic uremic syndrome.
Strobel S; Abarrategui-Garrido C; Fariza-Requejo E; Seeberger H; Sánchez-Corral P; Józsi M
Kidney Int; 2011 Aug; 80(4):397-404. PubMed ID: 21677636
[TBL] [Abstract][Full Text] [Related]
14. CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS).
Caillaud C; Zaloszyc A; Licht C; Pichault V; Frémeaux-Bacchi V; Fischbach M
Pediatr Nephrol; 2016 Jan; 31(1):157-61. PubMed ID: 26399238
[TBL] [Abstract][Full Text] [Related]
15. Complement factor H and hemolytic uremic syndrome.
Zipfel PF; Skerka C; Caprioli J; Manuelian T; Neumann HH; Noris M; Remuzzi G
Int Immunopharmacol; 2001 Mar; 1(3):461-8. PubMed ID: 11367530
[TBL] [Abstract][Full Text] [Related]
16. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome.
Goicoechea de Jorge E; Harris CL; Esparza-Gordillo J; Carreras L; Arranz EA; Garrido CA; López-Trascasa M; Sánchez-Corral P; Morgan BP; Rodríguez de Córdoba S
Proc Natl Acad Sci U S A; 2007 Jan; 104(1):240-5. PubMed ID: 17182750
[TBL] [Abstract][Full Text] [Related]
17. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome.
Ying L; Katz Y; Schlesinger M; Carmi R; Shalev H; Haider N; Beck G; Sheffield VC; Landau D
Am J Hum Genet; 1999 Dec; 65(6):1538-46. PubMed ID: 10577907
[TBL] [Abstract][Full Text] [Related]
18. Atypical haemolytic uraemic syndrome and mutations in complement regulator genes.
Dragon-Durey MA; Frémeaux-Bacchi V
Springer Semin Immunopathol; 2005 Nov; 27(3):359-74. PubMed ID: 16189652
[TBL] [Abstract][Full Text] [Related]
19. A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome.
Francis NJ; McNicholas B; Awan A; Waldron M; Reddan D; Sadlier D; Kavanagh D; Strain L; Marchbank KJ; Harris CL; Goodship TH
Blood; 2012 Jan; 119(2):591-601. PubMed ID: 22058112
[TBL] [Abstract][Full Text] [Related]
20. Atypical HUS and complement dysregulation.
Goodship TH
J Am Soc Nephrol; 2006 Jul; 17(7):1775-6. PubMed ID: 16790505
[No Abstract] [Full Text] [Related]
[Next] [New Search]
